Member Info for ak_gabba

that was my query about the q32s gggg21. was wondering if they had been specifically earmarked for a customer.

would also love to see a break down of where these machines are being sold to. each one is a potential revenue generator across all of their catalogue.

neilrich3,
The professor is certainly well placed and highly respected in that subject!
https://wellcome.org/news/global-intelligence-superbugs-vital-stop-antibiotic-resistance

I understand focus was given to covid-19 (COG) however I suspect she will return to the research of bacteria, it's spread and anti-biotic resistance in due course.

The lft are flown in. Bidstats shows the flights from China for these

ShaunP,

From gov link
"Where new variants or mutations are identified, the technology could be adapted to test for them as well, meaning the technology can be easily deployed to track the variants of most concern."

From RNS
"Due to the concerning properties, Novacyt recognises the importance and need to closely monitor VOC and significant mutations. Therefore, VariPLEX™ is a fully customisable assay panel and new mutations can be added to the panel within weeks as and when they become relevant."

When does join the dots turn into a game of SNAP?

good game good game

I noticed the RNS mentioned Q32 and not the Q16.

"VariPLEX™ can be deployed on-site in near-patient settings to generate results in under two hours to facilitate same-day patient and public health decision making when using the Company's q32 instruments or in any central laboratory with an open platform instrument with the ability to detect across at least four fluorescent channels."

Is this because the Q16 does not have four fluorescent channels?
Can this also explain why the Q16 was specifically mentioned in the VersaLab RNS and not the Q32? Is Q32 earmarked for the VariPLEX while Q16 is earmarked for VersaLab?

They released an RNS for Y453F which was originally found in minks

https://www.lse.co.uk/rns/NCYT/tests-for-new-strains-of-covid-19-and-avian-flu-amj7i32dk8wyhar.html

how much does a RNS cost?

https://www.youtube.com/watch?v=oiZ5Z5Y3CmI&ab_channel=TheIndependent

https://www.gov.scot/binaries/content/documents/govscot/publications/factsheet/2020/09/covid-19-advisory-group-evidence-papers-may-2020/documents/utility-of-whole-genome-sequencing-for-sars-cov-2-11-may-2020/utility-of-whole-genome-sequencing-for-sars-cov-2-11-may-2020/govscot%3Adocument/Utility%2Bof%2Bwhole%2Bgenome%2Bsequencing%2Bfor%2BSARS-CoV-2%2B%252811%2BMay%2B2020%2529.pdf

It's already in place. I think the funding is to support and expand

I think pre covid they left them as their own entities either so they didn't impact any sales negatively or due to the cost involved in bringing them all together under the same umbrella. Probably both. However now they are cash rich and looking towards growth in all or as many areas as possible coupled with a recent acquisition and perhaps more in the not too distant future there is now a need to bring everything together. This makes perfect sense and is very encouraging.

Milcait, it's actually showing 53 results for open jobs in linkedin for novacyt worldwide

I know what you are saying. The tests performed are a good number. Happy thoughts though maybe they are waiting on all the new installations reporting and we will see that number increase.

Never seen that before however they are still reporting the amount of tests performed on all pillars. Scroll down to tests conducted by pillar and select daily data

I noticed this on the news today
https://www.france24.com/en/france/20210316-france-investigating-new-coronavirus-variant-detected-in-brittany
I also spotted a difference in the detection level reported. The latest report i can find prior to the re branding is
https://www.genesig.com/assets/files/COVID_19_Specificity_Statement_issue_51.pdf
The latest one is here
https://www.genesig.com/assets/files/Bioinformatician_Report_WC_1st_March_Issue_541.pdf

There is a significant increase in the sequences analysed however a slight drop in the detection levels. Could this be the issue with this new variant that the French have issues with? I wasn't able to find any further info regarding that. Does anyone have more info regarding this?

Also nice to see they have updated the notes section at the bottom to include the TVG validation

Technologies Validation Group (TVG) Validation
The independent TVG performance evaluation performed at four NHS sites confirmed that the performance of
the PROMateTM assay aligns with the acceptable performance characteristics for sensitivity and specificity
of the testing product. Primer Design Ltd PROmate direct qRT-PCR (publishing.service.gov.uk).

As at dates and percentages
30/11/2020 3.54%
12/01/2021 2.95%
25/01/2021 3.02%
10/03/2021 2.99%
11/03/2021 3.00%
12/03/2021 2.81%

eplex gets mentioned a lot

https://genmarkdx.com/int/eplex-system/

"ePlex® revenue of $152.6 million, an increase of 155% over 2019"
"ePlex® revenue of $45.4 million, an increase of 138% over the fourth quarter of 2019"
"Placed 70 net new ePlex analyzers in the fourth quarter of 2020, finishing the year with an installed base of 792 ePlex analyzers worldwide"
"Average annuity per analyzer of $220,000, compared to $148,000 in the fourth quarter of 2019"

I'm not seeing how they are better than the Q16/Q32 however perhaps that area of the business is more established with a history pre covid.

Would be interesting to find out how many Q16/32 are being sold and what their average annuity is. With a portfolio of 500+ tests this is the combined area that would be of most interest to a buyer.

excellent link Milcait, thanks for sharing. i've registered for this and already looking forward to it

"another 113 cases where the UK virus has acquired the E484 mutation which allows it to escape some of the immune response"

I think thats the concerning take from that.

BERB is one of the market makers

looks like Dean has figured out where it is. Cambridge Manor Nursing Home

https://mobile.twitter.com/Blad3sharp/status/1368991136325459970